Impact of early use of opioid in patients with advanced stage gastroenterological cancer

Impact of early use of opioid in patients with advanced stage gastroenterological cancer - Impact of early use of opioid in patients with advanced stage gastroenterological cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002916

Enrollment

Registered

2010-01-01

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroenterological cancer

Interventions

Group A: 2.5mg of OxiKnorm powder plus 2.1mg of Durotep MT Patch. When patients feel pain, 2.5mg of OxiKnorm powder may be administered as rescue treatment. Time inverval of the rescue treatment shoul

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with far advanced gastroenterological cancer and suffer from cancer pain.

Exclusion criteria

Exclusion criteria: nothing

Design outcomes

Primary

Measure	Time frame
Pain control, QOL, and safety in patients receiving opioid for 2 weeks	—

Countries

Japan

Contacts

Public ContactChikara Kunisaki

Yokohama City University Medical Center Gastroenterological Center

045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026